drugset

drugset / Trial / NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194 ↗

Phase 1/2 Recruiting 285 enrolled ModeX Therapeutics, An OPKO Health Company

RandomizedSequentialOpen-labelTreatment

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Timeline

Start: 2024-06-12
Primary completion: 2028-08
Completion: 2029-02

Publications

Dumbrava E, Minchom A, Henry J, Johnson M, Sommerhalder D, Merchan J, Heist R, Cabanas EG, Cotreau M, Goenaga AL, Burzyn D, Makris L, Culm K, Abbadessa G. MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. Future Oncol. 2026 Feb;22(3):305-312. doi: 10.1080/14796694.2025.2610468. Epub 2026 Jan 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDX2001	Unknown	—	Intravenous

Indications